Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
1. To compare efficacy of tofacitinib at doses of 5 mg BID (twice a day) and 10 mg BID versus placebo for treatment of rheumatological signs and symptoms of active PsA in subjects who have had an inadequate response in PsA to at least one TNF inhibitor. 2. To compare physical function status after administration of tofacitinib at doses of 5 mg BID and 10 mg BID versus placebo in subjects with active PsA who have had an inadequate response in PsA to at least one TNF inhibitor. 3. To compare the safety and tolerability of tofacitinib at doses of 5 mg BID and 10 mg BID versus placebo in subjects with active PsA who have had an inadequate response in PsA to at least one TNF inhibitor.
Critère d'inclusion
- Psoriatic arthritis (PsA)